Re: Great Presetation today

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Great Presetation today

in response to

Re: Great Presetation today

tada

posted on Oct 19, 2017 09:40AM

I think we are saying the same thing.

If the funds raised are through Zenith Capital Corp then this would be dilutive to the royalty preferred shares. If the funds are raised through Zenith Epigenetics Ltd, then it should not be dilutive to the royalty preferred shares. Is it possible to just raise funds through Zenith Epigenetics Ltd, since it is a subsidiary company 100% owned by Zenith Capital Corp?